Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 18/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.64 |
| ▸ | HRH2 | P25021 | 1/20 | 0.64 |
| ▸ | HTR1D | P28221 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | HTR3A | P46098 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8423110 | 0.88 | HTR4 (0.79) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7333331 | 0.86 | HTR4 (0.82) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7365338 | 0.85 | HTR4 (0.82) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7398429 | 0.84 | HTR4 (0.88) | HTR4 | |
| SCHEMBL7363818 | 0.84 | HTR4 (0.78) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| Oxalic Acid SCHEMBL7330235 | 0.82 | HTR4 (0.85) | HTR4 | |
| Piboserod SCHEMBL467339 | 0.82 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL6909544 | 0.82 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7374980 | 0.82 | HTR4 (0.78) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| Piboserod SCHEMBL30234609 | 0.82 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094989-A1 | 5-HT RECEPTOR MODULATING COMPOUNDS | SERODUS AS (NO) | 2012-04-19 | — | — | US | disclosed |
| EP-2414331-A1 | 5-HT RECEPTOR MODULATING COMPOUNDS | Serodus AS (NO) | 2012-02-08 | — | — | EP | disclosed |
| US-7834010-B2 | Modulators of peripheral 5-HT receptors | SERODUS AS (NO) | 2010-11-16 | — | — | US | disclosed |
| US-7834010-B2 | Modulators of peripheral 5-HT receptors | SERODUS AS (NO) | 2010-11-16 | — | — | US | disclosed |
| WO-2010112865-A1 | 5-HT RECEPTOR MODULATING COMPOUNDS | SERODUS AS (NO) | 2010-10-07 | — | — | WO | disclosed |
| EP-1701951-B1 | MODULATORS OF PERIPHERAL 5-HT RECEPTORS | SERODUS AS (NO) | 2010-02-10 | — | — | EP | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| US-20070254874-A1 | Modulators of Preripheral 5-Ht Receptors | BIO-MEDISINSK INNOVASJON (NO) | 2007-11-01 | — | — | US | disclosed |
| US-20070254874-A1 | Modulators of Preripheral 5-Ht Receptors | BIO-MEDISINSK INNOVASJON (NO) | 2007-11-01 | — | — | US | disclosed |
| US-5998409-A | GASTROINTESTINAL DISORDERS; CARDIOVASCULAR DISORDERS; NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1999-12-07 | — | — | US | disclosed |
| EP-0630376-B1 | CONDENSED INDOLE DERIVATIVES AS 5-HT4-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-02 | — | — | EP | disclosed |
| EP-0712406-B1 | CONDENSED INDOLE DERIVATIVES AS 5-HT 4-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-10-28 | — | — | EP | disclosed |
| US-5705498-A | Piperidine derivatives as 5-HT4 receptor antagonists | SMITHKLINE BEECHAM PLC. (GB) | 1998-01-06 | — | — | US | disclosed |
| EP-0712406-A1 | CONDENSED INDOLE DERIVATIVES AS 5-HT 4-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-05-22 | — | — | EP | disclosed |
| EP-0667867-A1 | PIPERIDINE DERIVATIVES AS 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995004737-A1 | CONDENSED INDOLE DERIVATIVES AS 5-HT4-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-02-16 | — | — | WO | disclosed |
| EP-0630376-A1 | CONDENSED INDOLE DERIVATIVES AS 5HT 4?-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-28 | — | — | EP | disclosed |
| WO-1994010174-A1 | PIPERIDINE DERIVATIVES AS 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-05-11 | — | — | WO | disclosed |
| WO-1993018036-A1 | CONDENSED INDOLE DERIVATIVES AS 5HT4-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029979-A1 | 5-HTX MODULATORS | HTR7, HTR5A, HTR2C | HTR4 9/4885CHRM2 293/4885ADRA2B 62/4885 |
| US-20070254874-A1 | Modulators of Preripheral 5-Ht Receptors | HTR4, HTR5A, HTR6 | HTR4 1/4885CHRM2 163/4885ADRA2B 351/4885 |
| US-20120094989-A1 | 5-HT RECEPTOR MODULATING COMPOUNDS | HTR5A, HTR1A, HTR2A | HTR4 9/4885CHRM2 417/4885ADRA2B 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.